Area of research
Pharmacology · Immunology
Research interest
Research interests include Pharmacogenetics and Drug Metabolism, Psoriasis: Treatment and Pathogenesis, Pharmaceutical studies and practices, and Drug Transport and Resistance Mechanisms.
Impact of CYP and ABCB1 Polymorphisms on Bortezomib-Induced Adverse Events in Multiple Myeloma.
Role of Pharmacogenetics on Tramadol Pharmacokinetics: A Population Pharmacokinetic Model.
Impact of SLCO1B1 and ABCB1 variants on statin efficacy and toxicity in a Tunisian population
Impact of Genetic Variation in Adrenergic Receptors on β-Blocker Effectiveness and Safety in Cardiovascular Disease Management: A Systematic Review.
Pharmacogenetic Biomarkers of Ibrutinib Response and Toxicity in Chronic Lymphocytic Leukemia: Insights from an Observational Study.
Apixaban kinetics could be influenced by sex, cytochrome P450 enzymes and SLC6A2 transporter.
Transcriptomic profiling unveils novel therapeutic options for drug-resistant temporal lobe epilepsy.
Non-Inferiority Study of Two Capsaicin Formulations for Painful Diabetic Neuropathy.
Impact of Genetic Variants on Pregabalin Pharmacokinetics and Safety.
Analgesic Effect of a Novel Intravenous Ibuprofen-Low-Dose Tramadol Combination: A Multimodal Approach to Moderate-to-Severe Postoperative Dental Pain.
Association of HLA-B*53 with DRESS syndrome in patients treated with raltegravir: a cohort study and literature review
Design of an Array to Evaluate Biomarkers of Response to Biological Treatments in Inflammatory Bowel Disease
Effect of Genetic Variants on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Involvement of <i>ABCG2</i>, <i>SLCO1B1</i> and <i>NAT2</i>.
Impact of <i>STAT6</i> Variants on the Response to Proton Pump Inhibitors and Comorbidities in Patients with Eosinophilic Esophagitis.
Impact of CYP2D6 and CYP2B6 phenotypes on the response to tramadol in patients with acute post-surgical pain.
Update on the PriME-PGx initiative: evolution of pharmacogenetics in daily clinical practice.
Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers.
An Investigational Study on the Role of <i>CYP2D6</i>, <i>CYP3A4</i> and <i>UGT</i>s Genetic Variation on Fesoterodine Pharmacokinetics in Young Healthy Volunteers.
Response to "What is the Current Clinical Impact of the CYP2C:TG Haplotype?"
SLCO1B1 and ABCG2 genotype-informed phenotypes are related to variation in ramipril exposure.
Genetic Variation in <i>CYP2D6</i>, <i>UGT1A4</i>, <i>SLC6A2</i> and <i>SLCO1B1</i> Alters the Pharmacokinetics and Safety of Mirabegron.
Use of Exposure Data to Establish Causality in Drug-Adverse Event Relationships: An Example with Desvenlafaxine.
“Transcriptomic Profiling Unveils Novel Therapeutic Options for Drug-Resistant Temporal Lobe Epilepsy”
Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity.
Identification of Transporter Polymorphisms Influencing Metformin Pharmacokinetics in Healthy Volunteers.
NAT2 phenotype alters pharmacokinetics of rivaroxaban in healthy volunteers
Genetic Variation in <i>CYP2D6</i> and <i>SLC22A1</i> Affects Amlodipine Pharmacokinetics and Safety.
Dasatinib-induced spleen contraction leads to transient lymphocytosis.
Preemptive <i>TPMT</i> Genotyping and Adherence to Genotype-Based Therapeutic Recommendations Reduces the Healthcare Cost in Patients Receiving Azathioprine or 6-Mercaptopurine for Autoimmune Diseases.
Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide.